Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | Tirzepatide | Type 1 diabetes | Phase 3 | Enrollment Initiation | Subcutaneous | Endocrinology |
| Eli Lilly and Company | Lasofoxifene + abemaciclib - (ELAINE-3) | ER+/HER2- breast cancer with an ESR1 mutation | Phase 3 | Enrollment Initiation | Oral | Oncology |
| Eli Lilly and Company | Brenipatide - (RENEW-ALC-2) | Alcohol Use Disorder (AUD) | Phase 3 | Trial Planned | Intranasal | Psychiatric |
| Eli Lilly and Company | Tirzepatide - (SURMOUNT-MMO) | Obesity | Phase 3 | Ongoing | Subcutaneous | Endocrinology |
| Eli Lilly and Company | Orforglipron - (ACHIEVE-5) | Type 2 diabetes | Phase 3 | Data Released | Oral | Endocrinology |
| Eli Lilly and Company | Mounjaro (tirzepatide) - (SURPASS-PEDS) | Type 2 diabetes in children and adolescents | Phase 3 | Data Released | Subcutaneous | Endocrinology |
| Eli Lilly and Company | MORF-057 - (GARNET) | Crohn's Disease | Phase 2 | Enrollment Initiation | Oral | Gastroenterology |
| Eli Lilly and Company | MORF-057-201 - (EMERALD-1) | Ulcerative colitis | Phase 2a | Data Released | Oral | Gastroenterology |
